Dernières nouvelles pour Smith Douglas Homes (NYSE:SDHC) Stock

Smith Douglas Homes

Smith Douglas Homes Corp is a company engaged in the design, construction, and sale of single-family homes in some of the highest growth and desirable markets in the Southeastern United States. It is organized into eight geographical divisions which comprise two reportable segments. Its Southeast segment consists of Atlanta, Central Georgia, Charlotte, Greenville, and Raleigh divisions. Its Central segment consists of Alabama, Houston, and Nashville divisions.

BWMN

Bowman Enters Agreement To Acquire e3i Engineers, Financed Through Combination Of Cash, Seller Notes and Convertible Note; Bowman Anticipates Deal Will Initially Operate At Annualized Net Service Billing Run Rate ~$2M

News

DEFT

DeFi Technologies' Subsidiary Valour Launches Eight New SEK-Denominated ETPs On Sweden's Spotlight Stock Market

Canaccord Genuity analyst Katie Lachapelle upgrades Energy Fuels (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UUUU#AMEX">UUUU</a>) from Speculative Buy to Buy and raises the price target from C$9.5 to C$9.75.

Upgrades

Price Target

Analyst Ratings

UUUU

Canaccord Genuity Upgrades Energy Fuels to Buy, Raises Price Target to C$9.75

JMP Securities analyst Nicholas Jones maintains ACV Auctions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACVA#NYSE">ACVA</a>) with a Market Outperform and raises the price target from $18 to $20.

ACVA

JMP Securities Maintains Market Outperform on ACV Auctions, Raises Price Target to $20

Organon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGN#NYSE">OGN</a>), a global healthcare company with a focus on women's health, today announced that the Phase 2 ELENA proof-of-concept study evaluating the investigational candidate OG-6219 in endometriosis-related pain did not meet its primary efficacy endpoint. OG-6219 is an oral 17β-hydroxysteroid dehydrogenase type 1 (HSD17B1) inhibitor, which Organon acquired through its acquisition of Forendo Pharma in 2021. In the study, OG-6219 did not demonstrate improvement in moderate-to-severe endometriosis-related overall pelvic pain compared to placebo. Based on these results, the company plans to discontinue the OG-6219 clinical development program.
"While these study results are disappointing, Organon remains committed to our long-term vision to create a better and healthier every day for all women including those living with endometriosis," said Juan Camilo Arjona Ferreira, M.D., Head of Research &amp; Development and Chief Medical Officer at Organon. "We are grateful to all the patients, caregivers, and investigators for their participation in and support of this study."
The randomized, double-blind, placebo-controlled, parallel-group, global multi-center Phase 2a/b study (<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05560646&amp;esheet=54284964&amp;newsitemid=20250702870387&amp;lan=en-US&amp;anchor=NCT05560646&amp;index=1&amp;md5=aeb9426ea542f0de34677cf468d5fbed">NCT05560646</a>) aimed to evaluate the efficacy, safety, and tolerability of three dose levels of OG-6219 in pre-menopausal women 18 to 49 years of age who have been surgically diagnosed with endometriosis with moderate-to-severe endometriosis-related pain. Eligible patients were randomized to receive one of three doses of OG-6219 or placebo orally twice a day. The primary efficacy endpoint was the change from the baseline cycle (placebo run-in cycle) to the last planned treatment cycle (third month of treatment exposure), in the mean endometriosis-related overall pelvic pain score (measured using an eleven-point numerical rating scale).

Biotech

Health Care

General

Organon's Phase 2 Elena Proof-of-concept Study Of OG-6219 In Endometriosis-related Pain Did Not Meet Its Primary Efficacy Endpoint, Discontinues The OG-6219 Clinical Development Program

VCIG

VCI Global Announces Launch Of Qsecore Encryption Platform

KSX Search Xcelerator's 9th Acquisition
Asset-light industrial equipment services business with recurring revenues and strong growth prospects
Purchase price of $22.4 million
Trailing 12-month unaudited revenue of $16.0 million
Trailing 12-month unaudited adjusted EBITDA of $4.2 million
CHICAGO, IL / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / July 2, 2025 / Kingsway Financial Services Inc. ("Kingsway" or the "Company"), the only publicly-traded US company employing the Search Fund model to acquire and build great businesses, today announced the acquisition of Roundhouse Electric &amp; Equipment Co., Inc. ("Roundhouse"), a leading provider of industrial-scale electric motor maintenance, repair, testing, and sales solutions based in Odessa, Texas, for a purchase price of $22.4 million, plus transaction expenses and a working capital adjustment.
The transaction closed on July 1, 2025, and was funded with $10.4 million in cash on hand and $11.0 million from a senior credit facility. As part of the transaction, the selling shareholders are maintaining an economic interest in the go-forward entity, reflecting their continued belief in the company's long-term prospects and their alignment with Kingsway's growth vision.

Kingsway Acquires Roundhouse Electric & Equipment For $22.4M, Plus Transaction Expenses And Working Capital Adjustment

JMP Securities analyst Andrew Boone downgrades CarGurus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARG#NASDAQ">CARG</a>) from Market Outperform to Market Perform and maintains the price target from $38 to $38.

Downgrades

CARG

JMP Securities Downgrades CarGurus to Market Perform, Maintains Price Target to $38

Organon's Phase 2 ELENA Proof-of-Concept Study Evaluating OG-6219 Did Not Meet Primary Efficacy Endpoint

Wolfe Research analyst Emmanuel Korch upgrades Visteon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VC#NASDAQ">VC</a>) from Peer Perform to Outperform.

Wolfe Research Upgrades Visteon to Outperform

Wolfe Research analyst Emmanuel Rosner downgrades Aptiv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APTV#NYSE">APTV</a>) from Outperform to Peer Perform.

APTV

Wolfe Research Downgrades Aptiv to Peer Perform

Wolfe Research analyst Andrew Rosivach downgrades Innovative Ind Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIPR#NYSE">IIPR</a>) from Outperform to Peer Perform.

IIPR

Wolfe Research Downgrades Innovative Ind Props to Peer Perform

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the financial sector.
<h3 class="wp-block-heading">Arbor Realty Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABR#NYSE">ABR</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 11.21%</li>
<li>Keefe, Bruyette &amp; Woods analyst Jade Rahmani maintained a Market Perform rating and cut the price target from $11.75 to $11 on May 6, 2025. This analyst has an accuracy rate of 68%.</li>
<li>JP Morgan analyst Richard Shane maintained an Underweight rating and cut the price target from $10.5 to $10 on May 5, 2025. This analyst has an accuracy rate of 67%.</li>
<li>Recent News: On May 2, Arbor Realty Trust posted mixed quarterly results.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest ABR <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0702">news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0702"><img loading="lazy" decoding="async" width="907" height="817" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02045826/image-20.png" alt="" class="wp-image-969972" style="width:698px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02045826/image-20.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02045826/image-20-300x270.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02045826/image-20-768x692.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<h3 class="wp-block-heading">The Western Union Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WU#NYSE">WU</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 11.16%</li>
<li>UBS analyst Timothy Chiodo maintained a Neutral rating and lowered the price target from $11 to $10.5 on April 24, 2025. This analyst has an accuracy rate of 60%.</li>
<li>Keefe, Bruyette &amp; Woods analyst Sanjay Sakhrani maintained a Market Perform rating and slashed the price target from $12 to $11 on April 24, 2025. This analyst has an accuracy rate of 61%.</li>
<li>Recent News: On April 23, Western Union posted in-line quarterly earnings.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest WU <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0702">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0702"><img loading="lazy" decoding="async" width="923" height="833" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02045850/image-21.png" alt="" class="wp-image-969973" style="width:605px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02045850/image-21.png 923w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02045850/image-21-300x271.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02045850/image-21-768x693.png 768w" sizes="(max-width: 923px) 100vw, 923px" /></a></figure>
<h3 class="wp-block-heading">Chimera Investment Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIM#NYSE">CIM</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 10.67%</li>
<li>UBS analyst Douglas Harter upgraded the stock from Neutral to Buy and raised the price target from $11.5 to $15 on May 14, 2025. This analyst has an accuracy rate of 69%.</li>
<li>Keefe, Bruyette &amp; Woods analyst Bose George maintained a Market Perform rating and raised the price target from $15 to $16 on Aug. 8, 2024. This analyst has an accuracy rate of 71%.</li>
<li>Recent News: On June 12, HomeXpress Mortgage Corp. agreed to be acquired by Chimera Investment Corporation.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0702">CIM news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0702"><img loading="lazy" decoding="async" width="918" height="812" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02045918/image-22.png" alt="" class="wp-image-969978" style="width:534px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02045918/image-22.png 918w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02045918/image-22-300x265.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02045918/image-22-768x679.png 768w" sizes="(max-width: 918px) 100vw, 918px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46192054/cramer-backs-this-mining-giant-after-1-6b-bet">Cramer Backs This Mining Giant After $1.6B Bet</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

Dividends

Pre-Market Outlook

Markets

Trading Ideas

Wall Street's Most Accurate Analysts Give Their Take On 3 Financial Stocks Delivering High-Dividend Yields

OpenAI CEO Sam Altman, in an internal message to OpenAI researchers, reportedly emphasized the importance of staying with OpenAI and hinted at possible compensation evaluations.
What Happened:&nbsp;In a message to OpenAI researchers on Monday, Altman made a strong case for staying with OpenAI,&nbsp;<a href="https://www.wired.com/story/sam-altman-meta-ai-talent-poaching-spree-leaked-messages/">reported</a>&nbsp;Wired. He suggested that OpenAI is the best place for those looking to develop artificial general intelligence (AGI) and hinted at possible compensation evaluations&nbsp;for the entire research organization.
Altman also criticized Mark Zuckerberg&#8217;s recruitment efforts, calling it &#8220;distasteful&#8221;. &nbsp;&#8220;..what Meta is doing will, in my opinion, lead to very deep cultural problems,&#8221; warned Altman. &nbsp;
He acknowledged that Meta has recruited some top talent but emphasized that they have struggled to attract their first-choice candidates, suggesting that many of their recruits are not fully committed to the company&#8217;s mission.
&nbsp;&#8220;Meta&nbsp;has gotten a few great&nbsp;people for sure, but on&nbsp;the whole, it is hard&nbsp;to overstate how much they&nbsp;didn&#8217;t get their top people.&#8221;
Altman then urged OpenAI researchers to remain with the company, expressing confidence in the organization&#8217;s research roadmap and its unique team and culture. He also emphasized OpenAI&#8217;s commitment to building AGI in a responsible manner, contrasting this with other companies&#8217; instrumental approach to AGI.
SEE ALSO:&nbsp;<a href="https://benzinga.com/crypto/25/07/46211872/bitcoin-ethereum-dogecoin-mirror-tech-stocks-sell-off-as-trumps-big-beautiful-bill-passes-senate-analyst-spots-rare-warning-for-btc" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum, Dogecoin Mirror Tech Stocks Sell-Off As Trump&#8217;s &#8216;Big Beautiful Bill&#8217; Passes Senate: Analyst Spots &#8216;Rare Warning&#8217; For BTC &#8211; Grayscale Bitcoin Mini Trust (BTC) Common units of fractio</a>
Why It Matters: Meta&#8217;s aggressive <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46178725/meta-pursues-superintelligence-with-new-openai-hires-stock-climbs-to-fresh-highs">recruitment drive</a> comes as part of a broader restructuring of the company&#8217;s AI division, aimed at developing advanced AI systems capable of outperforming humans. This move included the formation of Meta Superintelligence Labs, led by former Scale AI CEO Alexandr Wang and former GitHub CEO Nat Friedman.
Several former OpenAI employees joined the team, prompting OpenAI's chief research officer, Mark Chen, to remark that it felt like "someone has broken into our home and stolen something.
However, the recruitment drive has been marred by controversy. OpenAI <a href="https://www.benzinga.com/markets/tech/25/06/46132953/fake-news-former-engineer-joining-meta-refutes-sam-altmans-100m-golden-pass-accusation-to-poach-openai-talent">engineers </a>Lucas Beyer, Alexander Kolesnikov, and Xiaohua Zhai, who recently transitioned to Meta, refuted claims by Altman that they received a $100 million signing bonus.
Despite Meta&#8217;s efforts, OpenAI <a href="https://www.benzinga.com/markets/tech/25/06/46163057/meta-is-gonna-need-time-to-catch-up-says-hyperbolic-cto-yuchen-jin-as-openais-upcoming-open-source-release-outperforms-existing-chatgpt-model">remains confident</a> in its research roadmap and upcoming projects. Hyperbolic CTO Yuchen Jin recently stated that OpenAI&#8217;s upcoming open-source AI model outperforms existing ChatGPT options, suggesting that Meta may need time to catch up.
<ul class="wp-block-list">
<li>READ MORE: <a href="https://www.benzinga.com/news/topics/25/07/46195343/on-the-front-line-of-chinas-ai-ambitions-openai-flags-zhipu-ai-as-rising-rival-backed-by-1-4b-state-funding">On The &#8216;Front Line&#8217; Of China&#8217;s AI Ambitions: OpenAI Flags Zhipu AI As Rising Rival Backed By $1.4B State Funding</a> </li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

OpenAI's Sam Altman Hints At Compensation Evaluation Amid Meta's 'Distasteful' AI Talent Poaching Spree: Report

<ul>
<li>The combined company plans to launch ZELSUVMI&#x2122; for the treatment of molluscum contagiosum infections in July 2025</li>
<li>Concurrent with the closing of the merger, the combined company closed on a $50.1 million equity private placement</li>
<li>Combined company will operate under the name "Pelthos Therapeutics Inc." and will trade on the NYSE American exchange under the ticker symbol "PTHS" starting on July 2, 2025</li>
</ul>

CHRO

Pelthos Therapeutics Completes Merger With Channel Therapeutics, Closes $50.1M Private Placement, And Prepares For July 2025 ZELSUVMI Launch

Shattuck Labs, Inc. (Shattuck) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STTK#NASDAQ">STTK</a>), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that company management will participate in a DR3/TL1A focused panel discussion and participate in one-on-one meetings at the Leerink Partners Therapeutics Forum: I&amp;I and Metabolism on July 8–9, 2025 in Boston, MA.

STTK

Shattuck Labs Management To Participate In DR3/TL1A Focused Panel Discussion And In One-On-One Meetings At Leerink Partners Therapeutics Forum: I&I And Metabolism

Diversified Energy Promotes Michael Garrett To Chief Accounting Officer, Tapping 20-Year Industry Veteran To Lead Financial Reporting Teams

Invivyd, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>), today announced that it has formed a best-in-class clinical and translational study group, the SPEAR Study Group, with leading investigators focused on the biology and clinical disease or injury associated with chronic exposure to SARS-CoV-2 virus or mRNA vaccine-mediated spike protein. The SPEAR Study Group will structure and guide anticipated clinical trials evaluating the effects of broadly neutralizing anti-SARS-CoV-2 spike protein monoclonal antibody (mAb) therapy in people suffering from Long COVID or Post-Vaccination Syndrome (PVS), conditions believed to be mediated by persistent viral reservoirs or circulating spike protein. Persistent SARS-CoV-2 spike protein has been identified in both populations, and both populations have overlapping manifestations of apparent clinical disease. As many as 5% or more of Americans have reported recent Long COVID symptoms, an extraordinary medical burden that will continue to evolve as infections continue in the U.S. The SPEAR Study Group was initiated in response to a growing number of case reports and reported case series from across the U.S. suggesting meaningful symptom relief / remission of Long COVID following use of PEMGARDA&#xAE; (pemivibart), a monoclonal antibody currently authorized by the U.S. Food and Drug Administration (FDA) for the pre-exposure prophylaxis (prevention) of COVID-19 in certain immunocompromised individuals. PEMGARDA is not authorized for the treatment of Long COVID. While these emerging reports are anecdotal and uncontrolled, they collectively support a longstanding, mechanistically plausible hypothesis: that prolonged exposure to pathogenic SARS-CoV-2 spike protein or other forms of persistent virus or viral material may drive disease in some patients, and that reducing this burden through monoclonal antibody therapy may offer a promising therapeutic approach worthy of rigorous clinical investigation. Clinical research to be planned by the SPEAR Study Group is critical to exploring disease biology and evaluating efficacy endpoints that can enable registrational studies if appropriate in the future.
The SPEAR Study Group includes the following investigators and researchers who, along with Invivyd, will collaborate on the design and anticipated execution of relevant clinical trials:
<ul>
<li>Michael Peluso, M.D., MHS, Assistant Professor of Medicine, Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco</li>
<li>Amy Proal, Ph.D., Co-Founder and CEO, Polybio Research Foundation and Scientific Director, Mount Sinai Cohen Center for Recovery from Complex Chronic Diseases ("CoRE")</li>
<li>David Putrino, Ph.D., Nash Family Director of the Mount Sinai Cohen Center for Recovery from Complex Chronic Diseases ("CoRE") and Professor, Department of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai. &nbsp;</li>
</ul>
The SPEAR Study Group intends to launch collaborative, multi-center translational clinical research on Long COVID, including PVS, as soon as practicable, including use of next-generation monoclonal antibody candidates from Invivyd such as VYD2311.

Comments

Smith Douglas Homes

Actualités

Dernières nouvelles pour Smith Douglas Homes (NYSE:SDHC) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL